SynthesisFrontiers in psychology2026
Neuropsychological outcomes comparing deep brain stimulation and best medical treatment for Parkinson's disease: a systematic review and meta-analysis.
Synthesis in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Deep brain stimulation (DBS) is an established therapy for advanced Parkinson's disease (PD). However, its impact on neuropsychological outcomes remains controversial and lacks systematic integration. This study aims to systematically evaluate the effects of DBS on cognitive and neuropsychiatric symptoms in PD patients through a meta-analysis of randomized controlled trials (RCTs). Methods: A systematic search was conducted in databases including PubMed, Embase, the Cochrane Library, and Web of Science for RCTs comparing DBS with best medical treatment (BMT). Cognitive outcome measures included Verbal Fluency test, the Stroop Color and Word Test, the Wisconsin Card Sorting Test (WCST), and the Mattis Dementia Rating Scale (MDRS). Neuropsychiatric outcome measures encompassed Part I of the Unified Parkinson's Disease Rating Scale (UPDRS-I), the Beck Depression Inventory-II (BDI-II), the Montgomery-Asberg Depression Rating Scale (MADRS), as well as the Brief Anxiety Scale (BAS) and Beck Anxiety Inventory (BAI). Risk of bias was assessed using the Cochrane RoB 2 tool, and effect sizes were pooled using RevMan 5.4 software. Results: A total of 10 randomized controlled trials involving 1,274 patients were included. Meta-analysis results indicated that, compared to BMT, patients undergoing DBS showed a more significant decline in performance on Verbal Fluency test and the Stroop Color-Word Interference Test. No statistically significant differences were observed between the two groups regarding overall cognitive function, cognitive flexibility, depressive symptoms, anxiety symptoms, or overall neuropsychiatric symptoms. Sensitivity analysis suggested that the effect of DBS on anxiety symptoms may vary across studies, indicating a potential beneficial role of DBS in this domain. Conclusion: DBS treatment did not lead to widespread cognitive or neuropsychiatric decline in patients with PD based on group-level analyses. However, within the assessed cognitive domains, mild, specific negative effects were observed on higher-order executive functions. Clinical decision-making should incorporate individualized neuropsychological assessment and monitoring to balance the benefits of motor symptom improvement with potential cognitive risks. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard, this meta-analysis has been registered on the PROSPERO platform (Registration number: CRD420251273115).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.